Evaluation of Safety and Systemic Pharmacokinetics After Abicipar Pegol (AGN-150998) Intravitreal Injections in Japanese Patients With NEovascular Age-Related Macular Degeneration (PINE Study)
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 30 May 2018
At a glance
- Drugs Abicipar pegol (Primary)
- Indications Age-related macular degeneration
- Focus Pharmacokinetics
- Acronyms PINE Study
- Sponsors Allergan
- 23 May 2018 Status changed from recruiting to active, no longer recruiting.
- 30 Nov 2017 Status changed from not yet recruiting to recruiting.
- 10 Nov 2017 New trial record